Global Markets Direct’s, ‘Allergic Asthma – Pipeline Review, H2 2015′, provides an overview of the Allergic Asthma’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Allergic Asthma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Allergic Asthma and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

• The report provides a snapshot of the global therapeutic landscape of Allergic Asthma
• The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in the therapeutics development for Allergic Asthma and enlists all their major and minor projects
• The report summarizes all the dormant and discontinued pipeline projects
• A review of the Allergic Asthma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• A detailed assessment of monotherapy and combination therapy pipeline projects
• Coverage of the Allergic Asthma pipeline on the basis of target, MoA, route of administration and molecule type
• Latest news and deals relating related to pipeline products

Reasons to buy

• Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop strategic initiatives by understanding the focus areas of leading companies
• Identify and understand important and diverse types of therapeutics under development for Allergic Asthma
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Devise corrective measures for pipeline projects by understanding Allergic Asthma pipeline depth and focus of Indication therapeutics
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
• Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Allergic Asthma Overview 8
Therapeutics Development 9
Pipeline Products for Allergic Asthma - Overview 9
Pipeline Products for Allergic Asthma - Comparative Analysis 10
Allergic Asthma - Therapeutics under Development by Companies 11
Allergic Asthma - Therapeutics under Investigation by Universities/Institutes 13
Allergic Asthma - Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Allergic Asthma - Products under Development by Companies 17
Allergic Asthma - Products under Investigation by Universities/Institutes 19
Allergic Asthma - Companies Involved in Therapeutics Development 20
ALK-Abello A/S 20
Allergopharma Joachim Ganzer KG 21
Array BioPharma Inc. 22
Aslan Pharmaceuticals Pte. Ltd. 23
BioTech Tools s.a. 24
CSL Limited 25
Fountain Biopharma Inc. 26
GlaxoSmithKline Plc 27
Infinity Pharmaceuticals, Inc. 28
Kineta, Inc. 29
Mabtech AB 30
Marinomed Biotechnologie GmbH 31
NeoPharm Co., Ltd. 32
Novartis AG 33
Nuvo Research Inc. 34
Oxagen Limited 35
Panacea Biotec Limited 36
Peptinnovate Limited 37
Pharmaxis Limited 38
Portola Pharmaceuticals, Inc. 39
Protectimmun GmbH 40
Pulmatrix, Inc. 41
Stallergenes S.A. 42
sterna biologicals Gmbh & Co KG 43
Swecure AB 44
The International Biotechnology Center (IBC) Generium 45
Verona Pharma Plc 46
Allergic Asthma - Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Combination Products 48
Assessment by Target 49
Assessment by Mechanism of Action 51
Assessment by Route of Administration 53
Assessment by Molecule Type 55
Drug Profiles 57
(fluticasone propionate + salmeterol xinafoate) - Drug Profile 57
AcTMP-1 - Drug Profile 59
Arabinogalactan - Drug Profile 60
ARRY-502 - Drug Profile 61
ASLAN-004 - Drug Profile 62
ASM-8 - Drug Profile 63
beta-escin - Drug Profile 65
CSL-311 - Drug Profile 67
dalazatide - Drug Profile 68
Drug to Inhibit PI3 Kinase Delta for Asthma - Drug Profile 70
duvelisib - Drug Profile 71
FB-825 - Drug Profile 73
fevipiprant - Drug Profile 74
GNR-044 - Drug Profile 76
GSK-2245035 - Drug Profile 77
hdm-ASIT - Drug Profile 79
Lactococcus lactis G121 - Drug Profile 80
ligelizumab - Drug Profile 81
MK-8237 - Drug Profile 83
OC-000459 - Drug Profile 85
omalizumab biosimilar - Drug Profile 87
omalizumab biosimilar - Drug Profile 88
omalizumab biosimilar - Drug Profile 89
omalizumab biosimilar - Drug Profile 90
pemirolast potassium - Drug Profile 91
pentosan polysulfate sodium - Drug Profile 92
PIN-201601 - Drug Profile 93
PRT-2607 - Drug Profile 94
RPL-554 - Drug Profile 95
SB-010 - Drug Profile 98
SG-100 - Drug Profile 100
Small Molecule for Allergic Asthma - Drug Profile 101
Small Molecules for Allergic Asthma - Drug Profile 102
Small Molecules to Inhibit CaMKII for Allergic Asthma - Drug Profile 103
STG-320 - Drug Profile 104
SWE-01 - Drug Profile 106
Timothy Grass Pollen Allergen Extract - Drug Profile 107
Vaccine for Allergic Rhinitis and Allergic Asthama - Drug Profile 109
WF-10 liposomal - Drug Profile 110
Allergic Asthma - Recent Pipeline Updates 111
Allergic Asthma - Dormant Projects 134
Allergic Asthma - Discontinued Products 135
Allergic Asthma - Product Development Milestones 136
Featured News & Press Releases 136
Appendix 142
Methodology 142
Coverage 142
Secondary Research 142
Primary Research 142
Expert Panel Validation 142
Contact Us 142
Disclaimer 143

List of Tables

Number of Products under Development for Allergic Asthma, H2 2015 12
Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2015 13
Number of Products under Development by Companies, H2 2015 14
Number of Products under Investigation by Universities/Institutes, H2 2015 16
Comparative Analysis by Late Stage Development, H2 2015 17
Comparative Analysis by Clinical Stage Development, H2 2015 18
Comparative Analysis by Early Stage Development, H2 2015 19
Products under Development by Companies, H2 2015 20
Products under Development by Companies, H2 2015 (Contd..1) 21
Products under Investigation by Universities/Institutes, H2 2015 22
Allergic Asthma - Pipeline by ALK-Abello A/S, H2 2015 23
Allergic Asthma - Pipeline by Allergopharma Joachim Ganzer KG, H2 2015 24
Allergic Asthma - Pipeline by Array BioPharma Inc., H2 2015 25
Allergic Asthma - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H2 2015 26
Allergic Asthma - Pipeline by BioTech Tools s.a., H2 2015 27
Allergic Asthma - Pipeline by CSL Limited, H2 2015 28
Allergic Asthma - Pipeline by Fountain Biopharma Inc., H2 2015 29
Allergic Asthma - Pipeline by GlaxoSmithKline Plc, H2 2015 30
Allergic Asthma - Pipeline by Infinity Pharmaceuticals, Inc., H2 2015 31
Allergic Asthma - Pipeline by Kineta, Inc., H2 2015 32
Allergic Asthma - Pipeline by Mabtech AB, H2 2015 33
Allergic Asthma - Pipeline by Marinomed Biotechnologie GmbH, H2 2015 34
Allergic Asthma - Pipeline by NeoPharm Co., Ltd., H2 2015 35
Allergic Asthma - Pipeline by Novartis AG, H2 2015 36
Allergic Asthma - Pipeline by Nuvo Research Inc., H2 2015 37
Allergic Asthma - Pipeline by Oxagen Limited, H2 2015 38
Allergic Asthma - Pipeline by Panacea Biotec Limited, H2 2015 39
Allergic Asthma - Pipeline by Peptinnovate Limited, H2 2015 40
Allergic Asthma - Pipeline by Pharmaxis Limited, H2 2015 41
Allergic Asthma - Pipeline by Portola Pharmaceuticals, Inc., H2 2015 42
Allergic Asthma - Pipeline by Protectimmun GmbH, H2 2015 43
Allergic Asthma - Pipeline by Pulmatrix, Inc., H2 2015 44
Allergic Asthma - Pipeline by Stallergenes S.A., H2 2015 45
Allergic Asthma - Pipeline by sterna biologicals Gmbh & Co KG, H2 2015 46
Allergic Asthma - Pipeline by Swecure AB, H2 2015 47
Allergic Asthma - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 48
Allergic Asthma - Pipeline by Verona Pharma Plc, H2 2015 49
Assessment by Monotherapy Products, H2 2015 50
Assessment by Combination Products, H2 2015 51
Number of Products by Stage and Target, H2 2015 53
Number of Products by Stage and Mechanism of Action, H2 2015 55
Number of Products by Stage and Route of Administration, H2 2015 57
Number of Products by Stage and Molecule Type, H2 2015 59
Allergic Asthma Therapeutics - Recent Pipeline Updates, H2 2015 114
Allergic Asthma - Dormant Projects, H2 2015 137
Allergic Asthma - Discontinued Products, H2 2015 138

List of Figures

Number of Products under Development for Allergic Asthma, H2 2015 12
Number of Products under Development for Allergic Asthma - Comparative Analysis, H2 2015 13
Number of Products under Development by Companies, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 17
Comparative Analysis by Clinical Stage Development, H2 2015 18
Comparative Analysis by Early Stage Products, H2 2015 19
Assessment by Monotherapy Products, H2 2015 50
Number of Products by Top 10 Targets, H2 2015 52
Number of Products by Stage and Top 10 Targets, H2 2015 52
Number of Products by Top 10 Mechanism of Actions, H2 2015 54
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 54
Number of Products by Top 10 Routes of Administration, H2 2015 56
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 56
Number of Products by Top 10 Molecule Types, H2 2015 58
Number of Products by Stage and Top 10 Molecule Types, H2 2015 58